Other languages Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
40.26 ^USD	-1.59%		-0.94%	-5.05%

May. 14	Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing	MT
May. 08	Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing	May. 14
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study	Apr. 18
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson?s Disease	Apr. 18
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	Mar. 04
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 22
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions	Feb. 22
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports	Feb. 21
AbbVie CEO to Retire; COO Robert Michael Named Successor	Feb. 20
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	Feb. 12
Omzetdaling Abbvie valt mee	Feb. 02
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer	Jan. 22
Cerevel Therapeutics Holdings Insider Sold Shares Worth $424,700, According to a Recent SEC Filing	Dec. 28
Cerevel Therapeutics Holdings Insider Sold Shares Worth $331,608, According to a Recent SEC Filing	Dec. 27
Cerevel Therapeutics Holdings Insider Sold Shares Worth $571,972, According to a Recent SEC Filing	Dec. 22
Cerevel Therapeutics Holdings Insider Sold Shares Worth $259,144, According to a Recent SEC Filing	Dec. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Other languages

Filters